AveXis Inc is a clinical-stage gene therapy company. It is engaged in developing and commercializing novel treatments for patients suffering from rare and life-threatening neurological genetic diseases. Its product candidate is AVXS-101.
Our STA Research today shows that the stock is due for a 35% decrease in it’s stock valuation within a 6 to 12 month duration. Yahoo Finance Analyst Report indicates a 37% decrease. Our STA Research rating indicates the stock with a Bearish near term sentiment.